MEET OUR TEAM
Mike joined the Global BioAccess Fund in 2023 and serves as a Venture Partner. He brings deep expertise across the full spectrum of biotech, including management roles, operations, investing, and bench research.
​
Mike also currently serves as the Chief Strategy Officer for AI Proteins. Prior to his current roles with the Global BioAccess Fund and AI Proteins, Mike served as COO of OncoPep, an immunotherapy-based biotech company. Previously, he led the investment team at the American Cancer Society’s VC fund (BrightEdge) and worked as an Associate Principal in the Life Sciences Practice of the CRA consulting group where he led global engagements in therapeutic area strategy, asset strategy, pipeline optimization, pricing & market access, M&A, and corporate strategy, primarily in oncology and immunology.
​
Mike’s scientific experience includes co-founding SynActive Biosciences (a startup focused on stem cell-derived neuron technologies), and working as a Program Manager/Senior Scientist in the Biosciences Division at the US Department of Defense where he researched immunology and infectious disease with a focus on emerging pathogens and bio-terrorism threat agents. He has authored many publications and has presented his research at leading academic conferences.
Mike received a Master of Science in genetics and a Bachelor of Science in Bacteriology from the University of Wisconsin-Madison, and an MBA in Finance, Strategy, and Entrepreneurship from the University of Chicago Booth School of Business. He is conversant in German and Spanish.